Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lpath, Inc.
Not all of the key medtech deals of 2016 were blockbusters. Herein are some of the more interesting smaller deals of the year.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2016.
Obesity device firm Apollo Endosurgery and drug firm LPath Inc. have announced plans to merge in an agreement that is intended to transition the privately held Apollo into a NASDAQ-listed company.
Biogen's license for the sphingosine 1-phosphate (S1P) receptor modulator MT-1303 from Mitsubishi Tanabe for up to $544m makes a lot of sense, but with four S1P-targeting drugs approved or in late-stage development did Biogen execute a good deal too late to catch up with the competition?
- In Vitro Diagnostics
- Drug Discovery Tools
- Other Names / Subsidiaries
- Lpath Therapeutics Inc.
- Neighborhood Connections, Inc.